In medicine today – Cancer and the prorogation of clinical reality in favour of probabilistic outcomes

Retsas, Spyros

doi:10.2478/fco-2023-0033

Abstract

How essential is the randomised trial in cancer therapeutics? Is it conceivable that prospective randomised clinical trials in cancer medicine could, one day, safely be abandoned in favour of Phase II studies supplemented with real-world data from cancer centres, without detriment to the progress of cancer therapeutics or the welfare of cancer sufferers? If feasible, such practice could reduce the cost of new drug development, while freeing clinical investigators from the ethical burden of random allocation of treatment or indeed providing no therapy with the administration of a placebo to cancer sufferers.

References

Wechsler LR. Statins and Stroke - It’s Complicated. N Engl J Med 2020; 382:81–82
Search in Google Scholar Back to article
Jolobe Oscar M.P. Titration of antihypertensive therapy to mitigate the risk of falls. LETTERS TO THE EDITOR. Clinical Medicine 2022 Vol 22 No 6:597. DOI 10.7861/clinmed.Let.22.6.1
Open DOI Search in Google Scholar Back to article
Jenei K, Moraes FY, Gyawali B. Globalisation of clinical trials in oncology: a double-edged sword? BMJ Oncology 2023;2:e000163. doi:10.1136/bmjonc-2023-000163
Open DOI Search in Google Scholar Back to article
Kirkwood JM, Strawderman MH, Ernstoff Ms, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7–17.
Search in Google Scholar Back to article
Williams MV, De Takats P, Parmar M. Survival benefit in melanoma. J Clin Oncol, 1997; 15, No 5 (May), 2172.
Search in Google Scholar Back to article
Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ 2017;359: j4530 http://dx.doi.org/10.1136/bmj.j4530
Search in Google Scholar Back to article
Wise PH. Cancer drugs survival and ethics BMJ 2016;355: i5792
Search in Google Scholar Back to article
Van Oosterom At, Judson Ir, Verweij J, Stroobants S, Dumez H, Donato Di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen Os; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumours: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002 Sep;38 Suppl 5:S83–7. doi: 10.1016/s0959-8049(02)80608-6. PMID: 12528778.
Open DOI Search in Google Scholar Back to article
Rigo R, Doherty J, Koczka K, Kong S, Ding Pq, Cheng T, Cheung Wy, Monzon Jg. Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis. Curr Oncol. 2021 Oct 5;28(5):3978–3986. doi: 10.3390/curroncol28050338.
Open DOI Search in Google Scholar Back to article
Ioannidis JPA, Haidich A-B, Lau J. Any casualties in the clash of randomised and observational evidence? No—recent comparisons have studied selected questions, but we do need more data. BMJ 2001;322:879–80
Search in Google Scholar Back to article
Medical Research Council: Streptomycin treatment of pulmonary tuberculosis. BMJ 1948:769–782,
Search in Google Scholar Back to article
Hellman S, Hellman Ds: Of mice but not men: Problems of the randomized clinical trial. N Engl J Med 1991; 324:1585–1589.
Search in Google Scholar Back to article
Yokota T, Kojima S, Yamauchi H, Hatori M. Evidence-based medicine in Japan. www.thelancet.com 2005; Vol 366 July 9, 122.
Search in Google Scholar Back to article
WU J. Could evidence-based medicine be a danger to progress? www.thelancet.com 2005; Vol. 366 July 9, 122.
Search in Google Scholar Back to article

In medicine today – Cancer and the prorogation of clinical reality in favour of probabilistic outcomes

Abstract

Paradigm

My account